In 2009, French company Sanofi S.A.'s anticoagulant Lovenox
(enoxaparin sodium) was the top-selling hospital medicine in the U.S. with
sales of $2.7 billion.
But with the introduction of generic versions of the drug starting in 2010, the drug’s fortunes have taken a turn for the worse. A highly competitive market with multiple players has dragged down product prices and sales, Bloomberg Intelligence analyst Elizabeth Krutoholow told me.
Sales of Lovenox are down on the branded side due to generics and lower pricing, she said. In addition, branded blood thinners in a different class—the factor Xa class—such as Janssen’s Xarelto (rivaroxaban) and Bristol-Myers Squibb Co.’s Eliquis (apixiban) have been more popular because they are safer, she said. Sales of generic Lovenox also face market challenges. An uptick in generic approvals has created more competition, dragging prices and sales, Krutoholow said.
Momenta First on Market
Momenta Pharmaceuticals’s generic was the first generic version of the top-selling anticoagulant on the market. Partnering with Sandoz, the generics arm of pharmaceutical giant Novartis SA, Momenta introduced the generic in July 2010.
Momenta’s sales of its generic Lovenox product have been declining as additional generics eneterd the market and sales of the generic aren’t expected to contribute significantly to the company’s bottom line, according to Bloomberg Intelligence analyst Elizabeth Krutoholow.
Israeli company Teva Pharmaceuticals Industries Ltd. and Amphastar Pharmaceuticals Inc. also market generic versions of enoxaparin. And even though Amphastar’s generic, which it started marketing in January 2012, is the company’s largest product by net revenues, those product revenues have been on the decline. In 2014, Amphastar netted $107.5 million from generic Lovenox sales, but that number fell to $84.5 million in 2015, and declined further to $59.3 million in 2016, the company said.
Sanofi markets an authorized generic enoxaparin product through its subsidiary, Winthrop, and through Fresenius Kabi USA. Authorized generics are generic drug products introduced by branded companies, either directly or through partnering arrangements with other generic companies.
Read my full story on the Momenta suit here.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)